Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + Fentanyl

ApprovedTerminated

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Procedural Sedation

Conditions

Procedural Sedation, Regional Anesthesia Block, Orthopedic Surgery

Trial Timeline

Feb 1, 2011 → Mar 1, 2011

NCT ID

NCT01195103

About Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + Fentanyl

Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + Fentanyl is a approved stage product being developed by Eisai for Procedural Sedation. The current trial status is terminated. This product is registered under clinical trial identifier NCT01195103. Target conditions include Procedural Sedation, Regional Anesthesia Block, Orthopedic Surgery.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01195103	Approved	Terminated	Feb 1, 2011	Mar 1, 2011	Procedural Sedation

Competing Products

2 competing products in Procedural Sedation

See all competitors

Product	Company	Stage	Hype Score
AQUAVAN® (fospropofol disodium) Injection	Eisai	Phase 2/3	65
Dexmedetomidine + Chloral hydrate	Pfizer	Phase 2	51

Other Products from Eisai

MecobalaminApproved

MonteplaseApproved

E2020 + PlaceboApproved

Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved

DonepezilApproved